QQQ   352.19 (+0.97%)
AAPL   179.82 (+1.12%)
MSFT   324.62 (+0.38%)
META   265.30 (+0.64%)
GOOGL   122.14 (-0.29%)
AMZN   123.68 (+2.02%)
TSLA   232.87 (+3.70%)
NVDA   384.96 (+2.72%)
NIO   7.67 (-1.16%)
BABA   86.22 (+1.10%)
AMD   120.74 (+2.47%)
T   16.00 (-0.62%)
F   13.56 (-0.22%)
MU   65.01 (-3.06%)
CGC   0.70 (-2.70%)
GE   106.84 (+0.72%)
DIS   92.33 (-0.21%)
AMC   4.66 (-1.48%)
PFE   39.03 (+0.36%)
PYPL   64.14 (+0.16%)
NFLX   404.96 (+1.30%)
QQQ   352.19 (+0.97%)
AAPL   179.82 (+1.12%)
MSFT   324.62 (+0.38%)
META   265.30 (+0.64%)
GOOGL   122.14 (-0.29%)
AMZN   123.68 (+2.02%)
TSLA   232.87 (+3.70%)
NVDA   384.96 (+2.72%)
NIO   7.67 (-1.16%)
BABA   86.22 (+1.10%)
AMD   120.74 (+2.47%)
T   16.00 (-0.62%)
F   13.56 (-0.22%)
MU   65.01 (-3.06%)
CGC   0.70 (-2.70%)
GE   106.84 (+0.72%)
DIS   92.33 (-0.21%)
AMC   4.66 (-1.48%)
PFE   39.03 (+0.36%)
PYPL   64.14 (+0.16%)
NFLX   404.96 (+1.30%)
QQQ   352.19 (+0.97%)
AAPL   179.82 (+1.12%)
MSFT   324.62 (+0.38%)
META   265.30 (+0.64%)
GOOGL   122.14 (-0.29%)
AMZN   123.68 (+2.02%)
TSLA   232.87 (+3.70%)
NVDA   384.96 (+2.72%)
NIO   7.67 (-1.16%)
BABA   86.22 (+1.10%)
AMD   120.74 (+2.47%)
T   16.00 (-0.62%)
F   13.56 (-0.22%)
MU   65.01 (-3.06%)
CGC   0.70 (-2.70%)
GE   106.84 (+0.72%)
DIS   92.33 (-0.21%)
AMC   4.66 (-1.48%)
PFE   39.03 (+0.36%)
PYPL   64.14 (+0.16%)
NFLX   404.96 (+1.30%)
QQQ   352.19 (+0.97%)
AAPL   179.82 (+1.12%)
MSFT   324.62 (+0.38%)
META   265.30 (+0.64%)
GOOGL   122.14 (-0.29%)
AMZN   123.68 (+2.02%)
TSLA   232.87 (+3.70%)
NVDA   384.96 (+2.72%)
NIO   7.67 (-1.16%)
BABA   86.22 (+1.10%)
AMD   120.74 (+2.47%)
T   16.00 (-0.62%)
F   13.56 (-0.22%)
MU   65.01 (-3.06%)
CGC   0.70 (-2.70%)
GE   106.84 (+0.72%)
DIS   92.33 (-0.21%)
AMC   4.66 (-1.48%)
PFE   39.03 (+0.36%)
PYPL   64.14 (+0.16%)
NFLX   404.96 (+1.30%)
NASDAQ:IBRX

ImmunityBio (IBRX) Stock Forecast, Price & News

$2.99
-0.06 (-1.97%)
(As of 02:22 PM ET)
Compare
Today's Range
$2.85
$3.08
50-Day Range
$1.53
$6.41
52-Week Range
$1.21
$7.80
Volume
1.67 million shs
Average Volume
4.45 million shs
Market Capitalization
$1.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

ImmunityBio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
100.0% Upside
$6.00 Price Target
Short Interest
Healthy
23.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.80mentions of ImmunityBio in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$268,516 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.04) to ($0.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

246th out of 981 stocks

Biotechnology Industry

1st out of 6 stocks


IBRX stock logo

About ImmunityBio (NASDAQ:IBRX) Stock

ImmunityBio, Inc. is a clinical-stage biotechnology company that focuses on developing next-generation therapies and vaccines to enhance the immune system's ability to fight cancer and infectious diseases. Guided by its mission to improve patient outcomes, ImmunityBio harnesses cutting-edge immunotherapy and cell therapy platforms to stimulate and sustain robust immune responses. The company's dedication to innovative research and development sets it apart in biotech.

In the rapidly evolving field of biotechnology, ImmunityBio, Inc. has emerged as a prominent player dedicated to developing innovative therapies and vaccines that harness the natural power of the immune system to combat cancer and infectious diseases. With a comprehensive portfolio of immunotherapy and cell therapy platforms, the company aims to create durable and safe protection against diseases, bolstering the potential for improved patient outcomes. This article provides an in-depth analysis of ImmunityBio, Inc., encompassing its company overview, management team, financial information, valuation, market performance, industry analysis, growth opportunities, and risks and challenges.

Headquartered in California, ImmunityBio, Inc. operates with a global presence, leveraging its scientific expertise and strategic partnerships to advance its mission. ImmunityBio, Inc. offers a range of products and services centered around immunotherapy and cell therapy. These include novel cancer vaccines, targeted bi-specific fusion proteins, and personalized cell-based therapies. The company aims to provide patients with durable protection against diseases and unlock new treatment possibilities by employing a multifaceted approach.

The leadership team at ImmunityBio, Inc. plays a crucial role in driving the company's vision forward. Led by Executive Chairman and Global Chief Medical Officer Patrick Soon-Shiong, the team comprises seasoned professionals with diverse expertise in biotechnology, medicine, and business. Each member brings a wealth of experience and a strong track record of achievements, collectively contributing to the company's success.

In recent years, ImmunityBio, Inc. has demonstrated steady growth and financial resilience. The company has recorded increasing revenues, driven by the progress of its clinical programs and strategic partnerships. Moreover, ImmunityBio, Inc. has implemented efficient cost management strategies to improve profitability and optimize resources. These positive trends indicate the company's potential for long-term success.

ImmunityBio, Inc.'s valuation metrics, such as the price-to-earnings ratio and price-to-book ratio, demonstrate its strong growth prospects relative to industry peers. Investor sentiment remains favorable due to the company's robust pipeline, innovative therapies, and potential for market disruption. As a result, ImmunityBio, Inc.'s valuation continues to reflect optimism for future performance.

ImmunityBio, Inc. has exhibited a dynamic stock performance, with significant price movements and trading volume fluctuations. Recent news and events related to the company's clinical trial results, regulatory approvals, or strategic partnerships have influenced its share price. Investors closely monitor these developments to gauge the company's market position and growth potential.

Operating in the biotechnology sector, ImmunityBio, Inc. navigates a competitive landscape characterized by rapid advancements and intense research and development efforts. The company faces competition from established pharmaceutical companies and emerging biotech firms, all striving to bring innovative therapies to market. However, ImmunityBio, Inc. differentiates itself through its unique approach that focuses on leveraging the natural immune system.

The company's comprehensive portfolio of immunotherapy and cell therapy platforms provides a competitive advantage. ImmunityBio, Inc. aims to create long-lasting and durable responses against diseases by targeting the immune system, which sets it apart from traditional treatment modalities. This innovative strategy positions the company favorably in an industry increasingly recognizing immunotherapies' potential.

ImmunityBio, Inc. possesses several growth opportunities that can propel its future success. The company's robust pipeline and ongoing clinical trials offer the potential for regulatory approvals and commercialization of its therapies. The successful completion of pivotal trials and subsequent market entry can lead to revenue growth and increased market share.

Additionally, ImmunityBio, Inc. can explore expansion into new markets and indications. The company's immunotherapy and cell therapy platforms have applications beyond cancer and infectious diseases, providing avenues for diversification and broadening its target patient population. Expanding into emerging fields such as gene therapy or exploring synergistic partnerships with complementary biotech companies can further bolster its growth prospects.

While ImmunityBio, Inc.'s future outlook appears promising, it faces various risks and challenges inherent in the biotechnology industry. Regulatory hurdles, such as the stringent requirements for clinical trial approvals and market authorizations, can pose delays and uncertainties in the development and commercialization process. Adherence to rigorous safety and efficacy standards is paramount to gaining regulatory approvals and ensuring patient safety.

Market competition remains intense, with other biotech companies vying for similar target indications. The emergence of new technologies or therapies that outperform or disrupt existing treatment modalities may impact the market adoption of ImmunityBio, Inc.'s products. The company must continually innovate and stay at the forefront of scientific advancements to maintain a competitive edge.

Moreover, the biotechnology industry is subject to inherent scientific and clinical uncertainties. While ImmunityBio, Inc.'s therapies show promising results, there is always the possibility of unexpected outcomes or challenges during clinical trials. Robust risk management strategies, thorough research protocols, and continuous trial data monitoring are essential to mitigate these uncertainties.

Additionally, market dynamics, such as changes in reimbursement policies or healthcare regulations, can influence the adoption and commercial success of ImmunityBio, Inc.'s therapies. The company must adapt to evolving market conditions and navigate complex healthcare systems to ensure broad patient access to its innovative treatments.

Receive IBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter.

IBRX Stock News Headlines

New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
ImmunityBio (NASDAQ:IBRX) Shares Gap Up to $2.54
ImmunityBio (NASDAQ:IBRX) Trading Up 7.2%
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
ImmunityBio (NASDAQ:IBRX) Shares Down 5.9%
ImmunityBio: Q1 Earnings Snapshot
ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $6.22
ImmunityBio Inc Ordinary Shares
Why Is ImmunityBio (IBRX) Stock Down 54% Today?
See More Headlines

IBRX Price History

IBRX Company Calendar

Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IBRX
Fax
N/A
Employees
587
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+106.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-416,570,000.00
Net Margins
-73,393.17%
Pretax Margin
-73,527.47%

Debt

Sales & Book Value

Annual Sales
$240,000.00
Book Value
($1.12) per share

Miscellaneous

Free Float
97,530,000
Market Cap
$1.27 billion
Optionable
Optionable
Beta
1.58

Key Executives

  • Patrick Soon-Shiong
    Executive Chairman & Global Chief Medical Officer
  • Richard AdcockRichard Adcock
    President, Chief Executive Officer & Director
  • Leonard S. Sender
    Chief Operating Officer
  • David Sachs
    Chief Financial Officer
  • John H. Lee
    Chief Medical Officer













IBRX Stock - Frequently Asked Questions

Should I buy or sell ImmunityBio stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunityBio in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IBRX shares.
View IBRX analyst ratings
or view top-rated stocks.

What is ImmunityBio's stock price forecast for 2023?

2 analysts have issued twelve-month price targets for ImmunityBio's stock. Their IBRX share price forecasts range from $4.00 to $8.00. On average, they predict the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 106.2% from the stock's current price.
View analysts price targets for IBRX
or view top-rated stocks among Wall Street analysts.

How have IBRX shares performed in 2023?

ImmunityBio's stock was trading at $5.07 at the beginning of the year. Since then, IBRX shares have decreased by 42.6% and is now trading at $2.91.
View the best growth stocks for 2023 here
.

Are investors shorting ImmunityBio?

ImmunityBio saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 24,960,000 shares, a decline of 16.7% from the April 30th total of 29,980,000 shares. Based on an average daily trading volume, of 5,960,000 shares, the days-to-cover ratio is presently 4.2 days. Approximately 23.0% of the company's stock are sold short.
View ImmunityBio's Short Interest
.

When is ImmunityBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our IBRX earnings forecast
.

What is ImmunityBio's stock symbol?

ImmunityBio trades on the NASDAQ under the ticker symbol "IBRX."

Who are ImmunityBio's major shareholders?

ImmunityBio's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.60%), Armistice Capital LLC (1.33%), State Street Corp (0.61%), Pictet Asset Management SA (0.56%), Geode Capital Management LLC (0.45%) and JPMorgan Chase & Co. (0.37%). Insiders that own company stock include Barry J Simon, Cheryl Cohen, John Owen Brennan, Michael D Blaszyk and Richard Adcock.
View institutional ownership trends
.

How do I buy shares of ImmunityBio?

Shares of IBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunityBio's stock price today?

One share of IBRX stock can currently be purchased for approximately $2.91.

How much money does ImmunityBio make?

ImmunityBio (NASDAQ:IBRX) has a market capitalization of $1.27 billion and generates $240,000.00 in revenue each year.

How many employees does ImmunityBio have?

The company employs 587 workers across the globe.

How can I contact ImmunityBio?

ImmunityBio's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The official website for the company is immunitybio.com. The company can be reached via phone at (858) 633-0300 or via email at investors@nantkwest.com.

This page (NASDAQ:IBRX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -